Merck Scores Cholesterol Pipeline Milestone with Oral PCSK9 Candidate

Merck's (NYSE:MRK) oral PCSK9 candidate has met its main and key secondary study goals in a pivotal lipid-lowering study, marking a significant milestone for the company's cholesterol pipeline.

The study result is important because it points to an oral path in a class of medicines that has long relied on injectable formats. An once-daily tablet that meaningfully lowers a key marker of cardiovascular strain could widen the reach of this therapy category to a far larger group of patients who prefer pills over injections.

Merck's diversified pipeline spans oncology, vaccines, cardiovascular care, and animal health, with the company leaning heavily on its flagship cancer immunotherapy. However, the cholesterol readout joins work across other fields aimed at building sources of growth as the flagship franchise matures.